InflammaSkin^® human psoriasis model

Hematoxylin and eosin staining was performed on 5 µm-thickness skin cross-sections. The histological analysis of the InflammaSkin^® model shows epidermal anomalies that are characteristic of psoriasis, in contrast to non-inflamed ex vivo skin models and the same model treated with the pro-inflammatory cocktail. All images are representative of the whole sample. Scale bar is 100 µm.

Epidermal activation is shown by the over-expression of the psoriasis-associated pro-inflammatory markers Keratin 16 (K16) and psoriasin (S100A7). Anti-S100A7 and anti-K16 immunofluorescence staining procedures were performed on 5 µm-thickness skin cross-sections. Red and cyan signals indicate a positive signal and DAPI-counterstain nuclei respectively. The dotted white lines represent the epidermal-dermal junction. Epidermal and dermal compartments are located above and below the dotted line respectively. All images are representative of the whole sample. Scale bar is 100 µm.

The analysis of cytokine levels in culture media at day 7 shows sustained secretion of IL-17A and IL-22 (IFN-γ and TNF-α as well as the lack of IL-4 expression, data not shown) compared to non-inflamed ex vivo skin models, supporting successful activation and differentiation of Th17/Th1 cells.
The models were either cultured under basal conditions (no induction), in the presence of the Th17/Th1 polarization cocktail (no T-Cell activation) and injected with activation cocktail and cultured in the presence of the Th17/Th1 polarization cocktail (InflammaSkin^®) for 7 days. Protein levels of IL-17A (A), IL-22 (B), INF-γ (C) were measured by ELISA (IL-22) and MSD in supernatant samples harvested after 7 days of culture. Lowest limit of detection (LLOD) is indicated by a dotted line for each cytokine. Data are expressed as mean value +/- SEM of pg/mL of secreted cytokines models obtained from 3 different donors. **P<.01

Building on the robust validation data outlined in the previous section, the InflammaSkin^® model empowers researchers to assess the efficacy of anti-inflammatory treatments with precision. This model is meticulously designed to evaluate therapies targeting key psoriasis pathways, including T cells and cytokines such as IL-17, IL-22, and TNF-α.

Whether you’re focusing on early intervention with prophylactic compounds (Day 0 administration) or addressing established inflammation with therapeutic treatments (Day 3 administration), InflammaSkin^® adapts to your research needs.

• Topical applications for localized treatment effects
• Subcutaneous delivery for systemic exposure profiles
• Systemic route to explore broader pharmacodynamic effects

With its proven validity and versatile application options, InflammaSkin^® is the ideal tool for accelerating the development of innovative anti-inflammatory therapies.